Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance
K. A. Cotter, J. Gallon, N. Uebersax, P. Rubin, K. D. Meyer, S. Piscuoglio, S. R. Jaffrey, M. A. Rubin
The paper maps m6A in prostate cancer and shows METTL3-low promotes therapy resistance through upregulated extracellular matrix proteins and hepatocyte nuclear factor-driven gene signatures.
bioRxiv · Jan 12, 2021Cancer Biology